Editing Prostate Biopsy

[[Category:Prostate Cancer]]

== Indications[https://www.baus.org.uk/_userfiles/pages/files/Publications/Transrectal%20Ultrasound%20%20Prostatic%20Biopsy%20FINAL.pdf] ==

# Detection of prostate cancer in patients with: 
## A raised PSA level (in the absence of urinary tract infection, acute urinary retention or acute prostatitis) 
## Abnormal digital rectal examination of the prostate
# Restaging and reassessment in patients for:
## Rising PSA following non-surgical treatment such as radiotherapy, brachytherapy, cryotherapy or HIFU 
## Active surveillance protocols in patients with known low grade cancer 
## Histology suspicious but not diagnostic for carcinoma
# As part of a protocol in an approved clinical trial

== Contraindications ==
# '''<span style="color:#ff0000">Significant coagulopathy</span>'''
# '''<span style="color:#ff0000">Severe immunosuppression</span>'''
# '''<span style="color:#ff0000">Acute prostatitis</span>'''

== Approach: Transrectal vs. Transperineal ==

* '''Cancer detection rates associated with transrectal versus transperineal biopsy route are not significantly different.[https://pubmed.ncbi.nlm.nih.gov/23659877/]'''

=== Transrectal biopsy ===

* Trajectory of needle is through rectum and into prostate
*'''Advantages[https://pubmed.ncbi.nlm.nih.gov/23659877/]'''
*#'''Patient preference/comfort'''
*#'''Patient cannot be placed into the lithotomy position'''
*#'''Clinician training/experience or lack of appropriate equipment for the transperineal approach.''' 
=== Transperineal biopsy ===
* Trajectory of needle is through skin (avoids rectum) and into prostate
*'''Advantages (3):'''
*# '''Reduced infectious and other complication rates'''
*# '''May detect anterior and apical cancers at a higher rate''' (prospective, randomized data are lacking and existing data are contradictory.)'''[https://pubmed.ncbi.nlm.nih.gov/23659877/]'''
*# '''Can be done in patients without a rectum''' (e.g., surgical extirpation, congenital anomaly)
* '''Disadvantages (1):'''
*# '''May need for more anesthesia''', but can be done under local anesthetic
*'''<span style="color:#ff0000">Transperineal biopsies may have some value in patients (3):[https://pubmed.ncbi.nlm.nih.gov/23659877/]</span>'''
*# '''<span style="color:#ff0000">Infectious complications with a prior biopsy</span>'''
*#'''<span style="color:#ff0000">Higher risk for biopsy-related infection</span>'''
*#'''<span style="color:#ff0000">Anterior lesions that may not be as easily accessible transrectally</span>'''
== Preparing for biopsy ==

=== Anti-coagulation ===
* '''<span style="color:#ff0000">Low-dose aspirin does not need to be discontinued</span>[https://pubmed.ncbi.nlm.nih.gov/24859439/]'''
* '''<span style="color:#ff0000">Warfarin and clopidogrel should be stopped 7-10 days before prostate biopsy</span>'''
* '''<span style="color:#ff0000">Novel oral anticoagulants apixaban, dabigatran, and rivaroxaban are stopped 2-5 days before</span>'''
** Rivaroxaban may increase stroke risk if stopped; therefore bridging with some other anticoagulant such as heparin is recommended.
* For patients with underlying coagulopathy or on warfarin, prostatic biopsy should not be performed until the INR has been corrected < 1.5 if the patient has low risk for a thromboembolic event. Because of the higher risk for thromboembolic events (e.g., mechanical valves) on warfarin, bridging anticoagulation with unfractionated heparin or low-molecular weight heparin is suggested.

=== Antibiotic prophylaxis</span> ===

==== Transrectal ====
*'''<span style="color:#ff0000">Recommended for all patients undergoing prostate biopsy</span>'''
* '''<span style="color:#ff0000">Regimen:</span>'''
** '''[https://pubmed.ncbi.nlm.nih.gov/31441676/ 2019 AUA Antibiotic Prophylaxis Guidelines]: fluoroquinolone OR 1st/2nd/3rd gen. cephalosporin (ceftriaxone commonly used) + aminoglycoside'''
** 2015 CUA Antibiotics Prophylaxis Guidelines: no specific regimen
** Campbell’s: For patients at risk for developing endocarditis or infection of prosthetic joints, pacemakers, and automated implanted cardiac defibrillators, prophylaxis should consist of intravenous ampicillin (vancomycin, if penicillin allergic) and gentamicin preoperatively, followed by 2 to 3 days of an oral fluoroquinolone.
** Presence of fluoroquinolone resistant organisms on a rectal swab culture may not always be associated with clinical infection. 
***A multi-institutional cohort study of 136 men undergoing rectal swab cultures immediately before biopsy found fluoroquinolone resistant E. coli in 22% of cultures. Patients received ciprofloxacin +/- gentamycin for prophylaxis. Post-biopsy fever occurred in 5 patients, and only 1 of them had a positive rectal screen for resistant E. coli.[https://pubmed.ncbi.nlm.nih.gov/21334021/]
** '''The use of targeted prophylaxis after rectal flora swabbing and culture has been shown to have some utility compared with empirical antibiotic prophylaxis in some series'''
* '''<span style="color:#ff00ff">2011 Cochrane review evaluating antibiotic prophylaxis for TRUS biopsy of the prostate</span>[https://pubmed.ncbi.nlm.nih.gov/21563156/]'''
** 19 studies including 3,599 patients.
** '''Comparing antibiotics vs. placebo/no antibiotics''' (9 trials): '''antibiotics significantly reduce risk of (5):'''
**# '''Bacteriuria''' (risk ratio (RR) 0.25)
**# '''UTI''' (RR 0.37)
**# '''Bacteremia''' (RR 0.67)
**# '''Fever''' (RR 0.39)
**# '''Hospitalization''' (RR 0.13)
**#* Most data derived from studies with quinolones
** '''Comparing antibiotics +/- enema, only the risk of bacteremia''' (RR 0.25, 95% CI 0.08-0.75) '''was diminished in the antibiotic + enema group'''
** '''Comparing short-course (1 day) versus long-course (3 days) antibiotics''' (7 trials): '''long course significantly better than short-course treatment only for bacteriuria''' (RR 2.09)
** Comparing '''s'''ingle versus multiple dose: significantly greater risk of bacteriuria for single-dose treatment (RR 1.98)
** Comparing oral versus systemic administration - intramuscular injection (IM), or intravenous (IV) - of antibiotics, no significant differences in the groups for bacteriuria, fever, UTI and hospitalization.
** Zani, Emerson L., Otavio Augusto Camara Clark, and Nelson Rodrigues Netto Jr. "[https://pubmed.ncbi.nlm.nih.gov/21563156/ Antibiotic prophylaxis for transrectal prostate biopsy.]" Cochrane Database of Systematic Reviews 5 (2011).

==== Transperineal ====

* Risk of infection is decreased compared to transrectal since trajectory avoids rectum
* '''<span style="color:#ff00ff">NORAPP Trial (2022)</span>[https://pubmed.ncbi.nlm.nih.gov/35839791/]'''
** Population: 555 patients referred for prostate biopsies
*** Excluded patients at high-risk (clinical suspicion of urinary tract infection together with a positive urine dipstick for leukocytes and nitrate, recurring or recent urinary tract infection (<1 month), indwelling urinary catheter, immunodeficiencies, high risk of infective endocarditis, or history of thromboembolic disease) of post-biopsy infection
*** All patients with a positive MRI underwent two to four biopsies per target. Systematic biopsies were done as an addition to target biopsies in biopsy naive patients and in all patients with a negative MRI.
** Randomized (open-label) to antibiotics (cefuroxime 1.5g IV or IM 30 minutes before biopsy) vs. no antibiotics
** Outcomes:
*** Primary: difference in the rate of urosepsis or urinary tract infections requiring hospitalisation up to 2 months after biopsy 
*** Secondary: difference in the rate of urinary tract infections not requiring hospitalisation by 2 months
** Results:
*** Primary outcome: no significant different in rate of urosepsis or UTI requiring hospitalisation up to 2 months after biopsy (0% antibiotics vs. 0% no antibiotics)
*** Secondary outcome: no significant difference in rate of UTI not requiring hospitalisation by 2 months (0.4% antibiotics vs. 1.1% no antibiotics)
**** NNT with antibiotic prophylaxis to avoid one UTI not requiring hospitalisation: 137
** '''Interpretation: In patients undergoing transperineal biopsy, antibiotics do not significantly reduce the risk of infections'''
** Jacewicz, Maciej, et al. "[https://pubmed.ncbi.nlm.nih.gov/35839791/ Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial.]" ''The Lancet Infectious Diseases'' (2022).

=== Cleansing Enema ===
* Advantages
**Decreases the amount of feces in the rectum, thereby producing a superior acoustic window for prostate imaging
**Effect on reducing infections is debatable
* Disadvantage
**Requires coordinating timing of biopsy to effect of cleansing enema
* '''2015 CUA Antibiotics Prophylaxis Guidelines: insufficient evidence to recommend routine use of enemas'''

=== Number and location of cores ===
* '''Approach'''
**'''Transrectal'''
***The extended 12-core systematic biopsy that incorporates apical and far-lateral cores is the current recommended method.
**** Previously, the standard number of cores was 6. However, it has been shown that increasing the number of cores from 6 to 12 significantly increases cancer detection rate.
***** Increasing the number of cores to 18 or 21 (often termed saturation biopsy) as an initial biopsy strategy does not appear to result in a similar increase from 6 to 12. Saturation biopsy is more likely to be considered in the setting of a prior negative biopsy, though in the era of MRI this may not be relevant.
**'''Transperineal'''
***20 cores (2 cores (different locations) taken from 5 sites on each side)[https://pubmed.ncbi.nlm.nih.gov/34048827/]
****5 sites
****#Posterior medial
****#Anterior medial
****#Posterior lateral
****#Anterior lateral
****#Base
**'''<span style="color:#ff0000">≥2 needle biopsy cores per target should be obtained in patients with suspicious prostate lesion(s) on MRI.[https://pubmed.ncbi.nlm.nih.gov/23659877/]</span>'''
***≥2 cores per target provides the most reproducible and accurate cancer detection rate.
**** The optimal number of biopsy cores per MRI target may differ based on multiple factors including
*****Patient characteristics (e.g., age, PSA, biopsy naïve versus prior biopsy)
*****Target characteristics (e.g., size, location, PIRADS classification)
*****Biopsy approach/technique (e.g., software fusion versus cognitive fusion, transrectal vs. transperineal).
****The incremental value in cancer detection is diminished after obtaining >3 cores per target.
***For prostate cancer risk group stratification, all cores from the same MRI target should be considered as a single core.
*'''The transitional zone and seminal vesicles are not routinely sampled because these regions have been shown to have consistently low yields for cancer detection at initial biopsy'''
** '''Isolated transition zone tumors without peripheral zone involvement occur < 5% of the time.'''
** '''Transitional zone and anteriorly directed biopsies may occasionally prove necessary to diagnose prostate cancer in those patients with persistently elevated PSA levels and prior negative biopsies. More recently, MRI is often used to detect and guide biopsies of these anterior tumors that may escape standard TRUS prostate biopsy'''
** The seminal vesicles are not routinely performed unless there is a palpable abnormality, with some authors recommending seminal vesicle biopsy when the PSA is > 30 or if brachytherapy is being considered
* '''When biopsy specimens are taken from different sextant areas of the prostate, they should be submitted to pathology in separate containers'''
** ''An AUA white paper recently outlined the recommended processing of prostate biopsy samples, and the review did not provide compelling evidence that individual site–specific labeling of cores benefits clinical decision making regarding the management of prostate cancer (Bjurlin et al, 2013). [still relevant?]''

== Technique ==

=== Equipment ===

* '''Ultrasound machine and biplanar probe'''
**Probe may be configured as side-fire vs. end-fire
***Randomized trials found no significant difference in prostate cancer detection rates between these two approaches[https://pubmed.ncbi.nlm.nih.gov/24725491/]
**'''The best visualization of the biopsy/needle path is in the sagittal plane'''
**Transperineal biopsy cannot be done with an end-fire probe or a side-fire probe with a short linear array[https://pubmed.ncbi.nlm.nih.gov/29409845/]
***Linear array needs to be long enough to visualize from just beyond the perineal skin to the apex of the prostate
* Disposable sheaths to cover the TRUS probes (e.g. condom)
**See [https://www.youtube.com/watch?v=izurJz0qXF4 Video] on preparing TRUS probe with lubrication and condom
*'''18-guage biopsy instrument'''
**The biopsy instrument advances the needle ≈0.5 cm and samples the subsequent ≈1.5 cm of tissue with the tip extending ≈0.5 cm beyond the area sampled. 
***Throw length/penetration depth/stroke length is the total distance the needle travels
***Notch length is the length of the tissue sample
***See Figure 1 in [https://pubmed.ncbi.nlm.nih.gov/30021242/ link]
***Bard Magnum has notch length of 19 mm and stroke length of 22 mm[https://pubmed.ncbi.nlm.nih.gov/30021242/]
**Therefore, when sampling the PZ, the needle tip may be placed 0.5 cm posterior to the prostate capsule before firing; advancing the needle to or through the capsule can result in sampling of more anterior tissue, missing the most common location of cancers.[https://www.us.elsevierhealth.com/campbell-walsh-wein-urology-9780323546423.html]
* '''Local anesthetic'''
**'''1% lidocaine without epinephrine'''
***'''Maximum safe dose: 3mg/kg[https://tam.nhsh.scot/formularies/highland-formulary/anaesthesia/local-anaesthesia/local-anaesthesia/]'''
****Maximum safe dose with epinephrine: 7mg/kg[https://tam.nhsh.scot/formularies/highland-formulary/anaesthesia/local-anaesthesia/local-anaesthesia/]
***1% lidocaine: contains 10 mg of lidocaine per 1 mL
***Maximum anesthetic volume in mL = maximum allowable dose (mg/kg) x (weight in kg/10) x (1/concentration of local anesthetic) = mL
****In 70 kg patient, can give 3 * 70/10 * 1/1 = 21 mL
***'''5 ml per side, is sufficient to provide pain relief[https://pubmed.ncbi.nlm.nih.gov/24725491/]'''
**1% lidocaine without epinephrine mixed with 8.4% sodium bicarbonate[https://pubmed.ncbi.nlm.nih.gov/34048827/]
***Can use up to 20-30cc
* 7 inch 22-guage spinal needle
*10cc syringe
*Ultrasound-specific lubricating gel
*Specimen containers
*Transperineal only
**PrecisionPoint Transperineal Access System
***Comprised of 3 components[https://pubmed.ncbi.nlm.nih.gov/29409845/]
****Clamp/rail subassembly
*****Distal portions of the rails are used to stabilize the assemble against the perineal skin
****Needle carriage with 4 apertures
****15 gauge access needle
*Prepare equipment
**Apply ultrasound-specific lubricating gel inside disposable sheath (e.g. condom)
**Insert probe into disposable sheath
**Apply constriction method so that lubrication jelly stays at tip of probe
**Apply ultrasound-specific lubricating gel over disposable sheath at tip of probe
**For transperineal only
***Assemble PrecisionPoint Transperineal Access System
****Apply Coban Self-Adherent Wrap to probe
****Put sliding carriage with ring over Coban
*****Stop on sliding carriage towards patient
*****Smaller holes of access canula towards patient
****Tighten ring so that sliding carriage aligned at 12 o'clock on ultrasound probe
**Prepare biopsy instrument

=== Anesthesia ===

* '''Approaches[https://pubmed.ncbi.nlm.nih.gov/16439219/]'''
** '''Regional anesthetic'''
***'''Periprostatic nerve block'''
****Nerves can be blocked with either unilateral or bilateral injection, around the apex or base of the gland (in the groove between the gland and seminal vesicles).
****Typically performed using a 7 inch 22-gauge spinal needle, and the biopsy channel of the ultrasound probe
****'''Aspirate the syringe before injecting to ensure that the vascular system has not been entered'''
****'''Method 1[https://pubmed.ncbi.nlm.nih.gov/8558671/][https://pubmed.ncbi.nlm.nih.gov/24725491/]'''
*****'''In the region of the neurovascular bundle at the base of the prostate, just lateral to the junction between the prostate and seminal vesicle'''
****** '''Can be easily identified as a hypoechoic (dark) area on TRUS'''
******See [https://pubmed.ncbi.nlm.nih.gov/8558671/ Figure 2 in link] and [https://www.semanticscholar.org/paper/Pain-during-Transrectal-Ultrasound-Guided-Prostate-Nazir/8c1020245b7d2c8f298441aa0355ffe577cd2fde/figure/3 Figure]
******See [https://www.youtube.com/watch?v=Mo3DO1mFTdU Video]
*****Ultrasound monitoring can confirm separation of the tissue planes caused by injection
*****The injection is performed twice, once either side the midline.
****Method 2 (transrectal)[https://pubmed.ncbi.nlm.nih.gov/16439219/]
*****A position just lateral to the midline, and away form the external sphincter is chosen. The needle is passed through rectal mucosa and local anaesthetic instilled, so that the anaesthetic pools within fascial layers (presumed to the Denonvillers' fascia) and bathes the posterior surface of the gland, from the apex up to the base.
*****The injection is performed twice, once either side of the midline.
****Conflicting evidence if direct infiltration into the prostate (intraprostatic injection) can augment the anesthetic benefit seen with periprostatic injection
***Pudendal nerve block[https://pubmed.ncbi.nlm.nih.gov/31374287/]
****Pudendal nerves are located 2cm lateral to anterior medial edge of anus and 3cm deep to skin
** Topical rectal anesthetic gel
** Variations in probe design
** Glyceryl trinitrate (GTN) paste
** Oral NSAIDs
** Inhaled nitrous oxide
** Intravenous analgesia

=== Transrectal ===

* See videos
**[https://www.youtube.com/watch?v=_DTbRREJsSk&list=PLmlqgyiBVx1EvCpovdviVhpHLlWhov98i&index=56 Transperineal biopsy (UColorado)]
**[https://www.youtube.com/watch?v=0p5aK69r6AI Transperineal biopsy (UMichigan)]
*'''Position: usually left lateral decubitus position with knees and hips flexed 90°; can also be done lithotomy'''
**Lithotomy is preferred for brachytherapy treatment planning or placement of fiducial gold markers for external-beam therapy

*Step by step
**Perform a DRE to (2):
**#Rule out any rectal pathology that would contraindicate insertion of the probe
**#Allow identification of any palpable prostatic abnormalities to which special attention could be paid during ultrasound examination
** Insert the lubricated ultrasound probe slowly and with pressure to dilate the anal sphincter.
** Adjust the gain to provide a uniform mid-gray image of the normal peripheral zone
*** The shading of the peripheral zone should be the homogenous gray standard by which other areas of the prostate are classified as hyperechoic, hypoechoic, or isoechoic.
** Scan the prostate, from the base to the apex
*** Evaluate for any hypoechoic lesions in the prostate
*** Scan in the axial/transverse plane, followed by the sagittal plane
**** Rotate probe counter-clockwise to access right lobe of prostate, and clockwise to access left lobe of prostate
** Measure the prostate size.
*** Measuring the prostate size is recommended prior to infiltration of local anaesthesia[14]
*** The prostate is measured in 3 planes. Typically, in the axial/transverse view, height and width are measured and in the sagittal/lateral view, length is measured
** Perform periprostatic nerve block
** Warn patients that they should expect a loud click when the biopsy gun is fired.
** Take biopsies following appropriate template
*** Use needle guide button on ultrasound machine, if available
*** 12-core
**** Lateral apex, mid, base
**** Medial apex, mid, base
**** The initial biopsy is taken midway between the mid-point of the prostate gland and the lateral margin
**** The probe is then rotated laterally and a subsequent biopsy is taken at the same level but more laterally placed to sample tissue from the anterior horn of the peripheral zone (PZ).
*** Use needle guide button on ultrasound machine, if available
*** It is important to place the biopsy needle correctly at the prostate capsule in order to sample the outer-most part of the PZ.
**** The biopsy needle travels a few millimetres forward of its position on TRUS and a frequent error is the insertion of the biopsy needle into the PZ prostatic tissue which results in the biopsy needle passing further into then gland and not sampling the area close to the capsule which is frequently the site of the PZ cancers.
*** It is important to ensure the biopsy sampling is spatially distributed correctly at the base, mid-gland and apex.
*** Care must be taken not to rebiopsy the same area particularly in smaller prostates as this can give misleading information about the extent of the cancer within the gland.
** Remove ultrasound probe and apply digital pressure to biopsied area to reduce bleeding
**Inform patient of reasons to return to hospital

* 

=== Transperineal ===

* See video accompanying [https://pubmed.ncbi.nlm.nih.gov/31374287/ article]
*See [https://www.youtube.com/watch?v=_DTbRREJsSk&list=PLmlqgyiBVx1EvCpovdviVhpHLlWhov98i&index=57 video]
*Position: usually lithotomy
*Step by step
**Perform a DRE to (2):
**#Rule out any rectal pathology that would contraindicate insertion of the probe
**#Allow identification of any palpable prostatic abnormalities to which special attention could be paid during ultrasound examination
**Secure scrotum anteriorly with tape
**Trim hair, if needed
**Prepare perineum with chlorhexidine 
**Perform pudendal nerve block, if performing without sedation
***Pudendal nerves located 2cm lateral to anterior medial edge of anal canal and 3cm deep to perineal skin
***Mark 2cm lateral to anterior medial edge on each side
***Puncture with needle at each mark and advance 3cm. Infiltrate with local anesthetic (5cc 1% lidocaine without epinephrine)
**Insert the lubricated ultrasound probe slowly and with pressure to dilate the anal sphincter.
***At this point the access needle is not engaged into the skin but rather is positioned several millimeters away from the perineum so that it can be used as an external gauge of the rotational angle of the linear ultrasound array
**Adjust the gain to provide a uniform mid-gray image of the normal peripheral zone
***The shading of the peripheral zone should be the homogenous gray standard by which other areas of the prostate are classified as hyperechoic, hypoechoic, or isoechoic.
**Scan the prostate, from the base to the apex
***Evaluate for any hypoechoic lesions in the prostate
***Scan in the axial/transverse plane, followed by the sagittal plane
****In axial view, right side of prostate will be on left side of screen and left side of prostate will be on right side of screen
****In sagittal view, rotate probe counter-clockwise to view right lobe of prostate, and clockwise to view left lobe of prostate
**Perform perineal skin block with local anesthetic 1cm lateral and 1cm superior to the superior aspect of the anus
***Inject 5cc local anesthetic on each side
**Perform periprostatic nerve block
***Pass spinal needle through access canula through skin marking
***Guide spinal needle towards apex of prostate under ultrasound vision
***Inject local anesthetic in between space of prostate and pelvic floor muscles, and along the track extending from the prostate to the skin
**Measure prostate size, if not done previously
***Measure the prostate in 3 planes.
****Typically, in the axial/transverse view, height and width are measured and in the sagittal/lateral view, length is measured
**Warn patients that they should expect a loud click when the biopsy gun is fired.
**Take biopsies following appropriate template
***Use needle guide button on ultrasound machine, if available
***Choose aperture position on device based on height of the intended area of biopsy and engage access needle into the perineal skin
****No more than 2 aperture positions should be needed to sample prostate
***20 cores (2 cores (different locations) taken from 5 sites on each side) +/- target(s)[https://pubmed.ncbi.nlm.nih.gov/34048827/]
****5 sites
****#Posterior medial
****#Anterior medial
****#Posterior lateral
****#Anterior lateral
****#Base
***3-4 cores from target(s)
**Remove ultrasound probe and apply pressure to perineum to reduce bleeding
**Inform patient of reasons to return to hospital

== Complications[https://pubmed.ncbi.nlm.nih.gov/28363690/] ==
# '''<span style="color:#ff0000">Bleeding</span>'''
##'''<span style="color:#ff0000">Hematuria''' '''(≈50%)</span>'''
##*'''Needs intervention (e.g. clot retention) in <1%'''
##'''<span style="color:#ff0000">Hematospermia''' '''(≈50%)</span>'''
##*'''Can persist >4 week after biopsy in ≈30%'''
##'''<span style="color:#ff0000">Rectal bleeding''' '''(≈30%)</span>'''
##*Needs intervention in ≈2.5%
##*'''Avoided with transperineal biopsy'''
#'''<span style="color:#ff0000">Infection''' (prostatitis, fever, epididymitis) 
#*'''</span>Transrectal (≈5-7%) higher than transperineal'''
#*'''Transrectal'''
#**'''<span style="color:#ff0000">Infection requiring hospitalization: ≈1-3%</span>'''
#***'''Rates of hospital admission and mortality after TRUS-biopsy[https://pubmed.ncbi.nlm.nih.gov/23234616/]'''
#****Population: Population-based cohort study of 75,190 men who underwent a transrectal ultrasound guided biopsy in Ontario, Canada, between 1996 and 2005
#****Results:
#*****The 30-day hospital admission rate increased significantly from 1% in 1996 to 4% in 2005, the majority (72%) of which were for infection related reasons.
#*****The overall 30-day mortality rate was 0.09% but did not change during the study period.
#****Conclusions: Hospital admission rates for complications following TRUS guided prostate biopsy have increased dramatically during the last 10 years primarily due to an increasing rate of infection related complications.
#***'''Risk factors for prostate biopsy-related infection (6):'''
#***#'''Non-White race'''
#***#'''Increased number of comorbidities'''
#***#'''Diabetes mellitus'''
#***#'''Prostate enlargement'''
#***#'''Foreign travel'''
#***#'''Recent antibiotic use'''
#'''<span style="color:#ff0000">Transient (≈1 month) lower urinary tract symptoms''' '''6-25%</span>'''
#'''<span style="color:#ff0000">Urinary retention''' '''<1%</span>'''
#'''<span style="color:#ff0000">Transient (≈1 month)  erectile dysfunction</span> <1%'''
# '''<span style="color:#ff0000">False-negative (variable rate based on PSA)</span>'''
#* Initial cancer detection rate for patients with a PSA between 4 and 10 μg/mL is 22%; subsequent biopsies for an elevated PSA result in a cancer detection rate of 10% on the second biopsy, 5% on the third, and 4% on the forth
#* Data from the large European screening study suggested that as the number of biopsy sessions increased to ultimately diagnose prostate cancer, the cancers diagnosed after several biopsy sessions were generally of lower grade and stage
#'''<span style="color:#ff0000">Identifying prostate cancer that does not require treatment</span>'''
##Discussing this risk prior to biopsy may optimize use of AS 

== Advanced and investigational techniques for prostate biopsy ==

* Newer imaging modalities allowing for the potential of targeted biopsy include Doppler to determine vessel density, determination of the elasticity of an area, endorectal MRI with dynamic contrast enhancement and diffusion weighting, and MRI spectroscopy
* '''Targeted prostate biopsy of a visible lesion on mpMRI can be performed using real-time ultrasound with (2):[https://pubmed.ncbi.nlm.nih.gov/23659877/]'''
**'''Software-based registration of mpMRI images OR'''
**'''Cognitive registration.'''
***'''Software-based registration'''
**** Combines the familiarity of real-time TRUS guidance with detailed information from a diagnostic multiparametric MRI and superimposes both images via software image reconstruction
****Disadvantages of software based fusion biopsy program:[https://pubmed.ncbi.nlm.nih.gov/23659877/]
*****Technical issues (e.g., software bugs, system crashes)
*****Operator error
*****Unusual anatomy (e.g., large prostates, previous transurethral resections of the prostate).
******The ability to perform cognitive fusion techniques using anatomic fiducial markers such as intraprostatic cysts may augment software-based fusion approaches in some cases such as to minimize the risk of misregistration.
*** '''Cognitive registration'''
**** Requires no additional equipment and relies on an experienced operator reviewing a suspicious lesion on MRI and then directing the biopsy needle in the direction of suspicious lesions during the standard TRUS biopsy procedure.
**** A primary disadvantage of this technique is the inability to record and confirm biopsy needle placement as well as interuser variability. In expert hands, this has been shown to be as good as software fusion
****Clinicians who adopt the cognitive fusion technique exclusively should undergo advanced training in MRI interpretation to optimize cancer detection.[https://pubmed.ncbi.nlm.nih.gov/23659877/]
***Conflicting evidence on cancer detection rates comparing software-based vs. cognitive registration[https://pubmed.ncbi.nlm.nih.gov/23659877/]

== Questions ==

# List complications of a TRUS biopsy
# What are some advantages/disadvantages of transperineal biopsy?

== Answers ==

# List complications of a TRUS biopsy
## Hematuria
## Hematospermia
## Rectal bleeding
## Infection
## Urinary retention
## False-negative
# What are some advantages/disadvantages of transperineal biopsy?
#*Advantages:
#*# Reduced infectious and other complication rates
#*# Improved identification of apical tumors
#*Disadvantages:
#*#May need more anesthesia

== Next Chapter: [[Management of Localized Prostate Cancer]] ==

== References ==

* Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, chap 109
*Lightner, Deborah J., et al. "[https://pubmed.ncbi.nlm.nih.gov/31441676/ Best practice statement on urologic procedures and antimicrobial prophylaxis.]" ''The Journal of Urology'' 203.2 (2020): 351-356.
*Harvey, C. J., et al. "[https://pubmed.ncbi.nlm.nih.gov/22844031/ Applications of transrectal ultrasound in prostate cancer.]" ''The British journal of radiology'' 85.special_issue_1 (2012): S3-S17.
*Zimmerman, Michael E., et al. "[https://pubmed.ncbi.nlm.nih.gov/31374287/ In-office transperineal prostate biopsy using biplanar ultrasound guidance: a step-by-step guide.]" ''Urology'' 133 (2019): 247.
*Meyer, Alexa R., et al. "[https://pubmed.ncbi.nlm.nih.gov/29409845/ Initial experience performing in-office ultrasound-guided transperineal prostate biopsy under local anesthesia using the precisionpoint transperineal access system.]" ''Urology'' 115 (2018): 8-13.